1. LyKN, XingJ, KlevensRM, et al.The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med2012;156:271. CrossRef

2. LavanchyD. The global burden of hepatitis C. Liver Int2009;29(Suppl 1):74. CrossRef

3. Mohd HanafiahK, GroegerJ, FlaxmanAD, et al.Global epidemiology of hepatitis C virus infection: new estimates of age‐specific antibody to HCV seroprevalence. Hepatology2013;57:1333. CrossRef

4. ArmstrongGL, AlterMJ, McQuillanGM, et al.The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology2000;31:777. CrossRef

5. WilliamsIT, BellBP, KuhnertW, et al.Incidence and transmission patterns of acute hepatitis C in the United States, 1982‐2006. Arch Intern Med2011;171:242. CrossRef

6. WardJW. The epidemiology of chronic hepatitis C and one‐time hepatitis C virus testing of persons born during 1945 to 1965 in the United States. Clin Liver Dis2013;17:1. CrossRef

7. Centers for Disease Control and Prevention (CDC). Progress toward prevention and control of hepatitis C virus infection–Egypt, 2001‐2012. MMWR Morb Mortal Wkly Rep2012;61:545.

8. ArmstrongGL, WasleyA, SimardEP, et al.The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med2006;144:705. CrossRef

9. SmithBD, MorganRL, BeckettGA, et al.Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945‐1965. MMWR Recomm Rep2012;61:1.

10. CornbergM, RazaviHA, AlbertiA, et al.A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int2011;31(Suppl 2):30. CrossRef

11. Martínez‐BauerE, FornsX, ArmellesM, et al.Hospital admission is a relevant source of hepatitis C virus acquisition in Spain. J Hepatol2008;48:20. CrossRef

12. NelsonPK, MathersBM, CowieB, et al.Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet2011;378:571. CrossRef

13. StramerSL, GlynnSA, KleinmanSH, et al.Detection of HIV‐1 and HCV infections among antibody‐negative blood donors by nucleic acid‐amplification testing. N Engl J Med2004;351:760. CrossRef

14. O′BrienSF, YiQL, FanW, et al.Current incidence and estimated residual risk of transfusion‐transmitted infections in donations made to Canadian Blood Services. Transfusion2007;47:316. CrossRef

15. Centers for Disease Control and Prevention (CDC). Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep2001;50(RR–5):1.

16. FinelliL, MillerJT, TokarsJI, et al.National surveillance of dialysis‐associated diseases in the United States, 2002. Semin Dial2005;18:52. CrossRef

17. ThompsonND, PerzJF, MoormanAC, et al.Nonhospital health care‐associated hepatitis B and C virus transmission: United States, 1998‐2008. Ann Intern Med2009;150:33. CrossRef

18. PatelPR, ThompsonND, KallenAJ, et al.Epidemiology, surveillance, and prevention of hepatitis C virus infections in hemodialysis patients. Am J Kidney Dis2010;56:371. CrossRef

19. KrauseG, TrepkaMJ, WhisenhuntRS, et al.Nosocomial transmission of hepatitis C virus associated with the use of multidose saline vials. Infect Control Hosp Epidemiol2003;24:122. CrossRef

20. FischerGE, SchaeferMK, LabusBJ, et al.Hepatitis C virus infections from unsafe injection practices at an endoscopy clinic in Las Vegas, Nevada, 2007‐2008. Clin Infect Dis2010;51:267. CrossRef

21. HauriAM, ArmstrongGL, HutinYJ. The global burden of disease attributable to contaminated injections given in health care settings. Int J STD AIDS2004;15:7. CrossRef

22. SulkowskiMS, RaySC, ThomasDL. Needlestick transmission of hepatitis C. JAMA2002;287:2406. CrossRef

23. TomkinsSE, ElfordJ, NicholsT, et al.Occupational transmission of hepatitis C in healthcare workers and factors associated with seroconversion: UK surveillance data. J Viral Hepat2012;19:199. CrossRef

24. SodeyamaT, KiyosawaK, UrushiharaA, et al.Detection of hepatitis C virus markers and hepatitis C virus genomic‐RNA after needlestick accidents. Arch Intern Med1993;153:1565. CrossRef

25. U.S. Public Health Service. Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Postexposure Prophylaxis. MMWR Recomm Rep2001;50(RR–11):1.

26. StruveJ, AronssonB, FrenningB, et al.Prevalence of antibodies against hepatitis C virus infection among health care workers in Stockholm. Scand J Gastroenterol1994;29:360. CrossRef

27. ZuckermanJ, ClewleyG, GriffithsP, et al.Prevalence of hepatitis C antibodies in clinical health‐care workers. Lancet1994;343:1618. CrossRef

28. ZaaijerHL, AppelmanP. Frijstein G. Hepatitis C virus infection among transmission‐prone medical personnel. Eur J Clin Microbiol Infect Dis2012;31:1473. CrossRef

29. YazdanpanahY, De CarliG, MigueresB, et al.Risk factors for hepatitis C virus transmission to health care workers after occupational exposure: a European case‐control study. Clin Infect Dis2005;41:1423. CrossRef

30. HosogluS, CelenMK, AkalinS, et al.Transmission of hepatitis C by blood splash into conjunctiva in a nurse. Am J Infect Control2003;31:502. CrossRef

31. SartoriM, La TerraG, AgliettaM, et al.Transmission of hepatitis C via blood splash into conjunctiva. Scand J Infect Dis1993;25:270. CrossRef

32. AlterMJ, ColemanPJ, AlexanderWJ, et al.Importance of heterosexual activity in the transmission of hepatitis B and non‐A, non‐B hepatitis. JAMA1989;262:1201. CrossRef

33. TerraultNA, DodgeJL, MurphyEL, et al.Sexual transmission of HCV among monogamous heterosexual couples: the HCV partners study. Hepatology2013;57:881. CrossRef

34. KaoJH, LiuCJ, ChenPJ, et al.Low incidence of hepatitis C virus transmission between spouses: a prospective study. J Gastroenterol Hepatol2000;15:391. CrossRef

35. VandelliC, RenzoF, RomanòL, et al.Lack of evidence of sexual transmission of hepatitis C among monogamous couples: results of a 10‐year prospective follow‐up study. Am J Gastroenterol2004;99:855. CrossRef

36. Centers for Disease Control and Prevention (CDC). Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV‐related chronic disease. MMWR Recomm Rep1998;47:1.

37. Centers for Disease Control and Prevention (CDC). Sexual transmission of hepatitis C virus among HIV‐infected men who have sex with men — New York City, 2005–2010. MMWR Morb Mortal Wkly Rep2011;60:945.

38. van de LaarTJ, van der BijAK, PrinsM, et al.Increase in HCV incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission. J Infect Dis2007;196:230. CrossRef

39. van der LaarT, PybusO, BruistenS, et al.Evidence of a large, international network of HCV transmission in HIV‐positive men who have sex with men. Gastroenterology2009;136:1609. CrossRef

40. MastEE, HwangLY, SetoDS, et al.Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. J Infect Dis2005;192:1880. CrossRef

41. PrasadMR, HoneggerJR. Hepatitis C virus in pregnancy. Am J Perinatol2013;30:149. CrossRef

42. GranovskyMO, MinkoffHL, TessBH, et al.Hepatitis C virus infection in the mothers and infants cohort study. Pediatrics1998;102:355. CrossRef

43. TovoPA, PalombaE, FerrarisG, et al.Increased risk of maternal‐infant hepatitis C virus transmission for women coinfected with human immunodeficiency virus type 1. Italian Study Group for HCV Infection in Children. Clin Infect Dis1997;25:1121. CrossRef

44. RobertsEA, YeungL. Maternal‐infant transmission of hepatitis C virus infection. Hepatology2002;36(5 Suppl 1):S106. CrossRef

45. CottrellEB, ChouR, WassonN, et al.Reducing risk for mother‐to‐infant transmission of hepatitis C virus: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med2013;158:109. CrossRef

46. European Mode of Delivery Collaboration. Elective caesarean‐section versus vaginal delivery in prevention of vertical HIV‐1 transmission: a randomised clinical trial. Lancet1999;353:1035. CrossRef

47. Management of Hepatitis C: 2002. NIH Consens State Sci Statements2002;19:1.

48. FeinstoneSM, KapikianAZ, PurcellRH, et al.Transfusion‐associated hepatitis not due to viral hepatitis type A or B. N Engl J Med1975;292:767. CrossRef

49. ChooQL, KuoG, WeinerAJ, et al.Isolation of a cDNA clone derived from a blood‐borne non‐A, non‐B viral hepatitis genome. Science1989;244:359. CrossRef

50. PileriP, UematsuY, CampagnoliS, et al.Binding of hepatitis C virus to CD81. Science1998;282:938. CrossRef

51. ScarselliE, AnsuiniH, CerinoR, et al.The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J2002;21:5017. CrossRef

52. EvansMJ, von HahnT, TscherneDM, et al.Claudin‐1 is a hepatitis C virus co‐receptor required for a late step in entry. Nature2007;446:801. CrossRef

53. PlossA, EvansMJ, GaysinskayaVA, et al.Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature2009;457:882. CrossRef

54. GrakouiA, WychowskiC, LinC, et al.Expression and identification of hepatitis C virus polyprotein cleavage products. J Virol1993;67:1385.

55. SelbyMJ, ChooQL, BergerK, et al.Expression, identification and subcellular localization of the proteins encoded by the hepatitis C viral genome. J Gen Virol1993;74:1103. CrossRef

56. BartenschlagerR, LohmannV, WilkinsonT, et al.Complex formation between the NS3 serine‐type proteinase of the hepatitis C virus and NS4A and its importance for polyprotein maturation. J Virol1995;69:7519.

57. KimJL, MorgensternKA, LinC, et al.Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell1996;87:343. CrossRef

58. TomeiL, FaillaC, SantoliniE, et al.NS3 is a serine protease required for processing of hepatitis C virus polyprotein. J Virol1993;67:4017.

59. MacdonaldA, HarrisM. Hepatitis C virus NS5A: tales of a promiscuous protein. J Gen Virol2004;85:2485. CrossRef

60. LesburgCA, CableMB, FerrariE, et al.Crystal structure of the RNA‐dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat Struct Biol1999;6:937. CrossRef

61. GosertR, EggerD, LohmannV, et al.Identification of the hepatitis C virus RNA replication complex in Huh‐7 cells harboring subgenomic replicons. J Virol2003;77:5487. CrossRef

62. Romero‐BreyI, MerzA, ChiramelA, et al.Three‐dimensional architecture and biogenesis of membrane structures associated with hepatitis C virus replication. PLoS Pathog2012;8:e1003056. CrossRef

63. MiyanariY, AtsuzawaK, UsudaN, et al.The lipid droplet is an important organelle for hepatitis C virus production. Nat Cell Biol2007;9:1089. CrossRef

64. ChangKS, JiangJ, CaiZ, et al.Human apolipoprotein e is required for infectivity and production of hepatitis C virus in cell culture. J Virol2007;81:13783. CrossRef

65. GastaminzaP, DrydenK, BoydB, et al.Ultrastructural and biophysical characterization of hepatitis C virus particles produced in cell culture. J Virol2010;84:10999. CrossRef

66. JiangJ, LuoG. Apolipoprotein E but not B is required for the formation of infectious hepatitis C virus particles. J Virol2009;83:12680. CrossRef

67. BengaWJ, KriegerSE, DimitrovaM, et al.Apolipoprotein E interacts with hepatitis C virus nonstructural protein 5A and determines assembly of infectious particles. Hepatology2010;51:43. CrossRef

68. AndréP, Komurian‐PradelF, DeforgesS, et al.Characterization of low‐ and very‐low‐density hepatitis C virus RNA‐containing particles. J Virol2002;76:6919. CrossRef

69. NielsenSU, BassendineMF, BurtAD, et al.Association between hepatitis C virus and very‐low‐density lipoprotein (VLDL)/LDL analyzed in iodixanol density gradients. J Virol2006;80:2418. CrossRef

70. SimmondsP, AlbertiA, AlterHJ, et al.A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology1994;19:1321. CrossRef

71. SimmondsP, BukhJ, CombetC, et al.Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology2005;42:962. CrossRef

72. SmithDB, PathiranaS, DavidsonF, et al.The origin of hepatitis C virus genotypes. J Gen Virol1997;78:321. CrossRef

73. ZeinNN, RakelaJ, KrawittEL, et al.Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group. Ann Intern Med1996;125:634. CrossRef

74. LauJY, DavisGL, PrescottLE, et al.Distribution of hepatitis C virus genotypes determined by line probe assay in patients with chronic hepatitis C seen at tertiary referral centers in the United States. Hepatitis Interventional Therapy Group. Ann Intern Med1996;124:868. CrossRef

75. NousbaumJB, PolS, NalpasB, et al.Hepatitis C virus type 1b (II) infection in France and Italy. Collaborative Study Group. Ann Intern Med1995;122:161. CrossRef

76. IsobeK, ImotoM, FukudaY, et al.Hepatitis C virus infection and genotypes in Japanese hemophiliacs. Liver1995;15:131. CrossRef

77. MartellM, EstebanJI, QuerJ, et al.Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol1992;66:3225.

78. CuevasJM, González‐CandelasF, MoyaA, et al.Effect of ribavirin on the mutation rate and spectrum of hepatitis C virus in vivo. J Virol2009;83:5760. CrossRef

79. NeumannAU, LamNP, DahariH, et al.Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon‐alpha therapy. Science1998;282:103. CrossRef

80. RongL, DahariH, RibeiroRM, et al.Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med2010;2:30ra32. CrossRef

81. EricksonAL, KimuraY, IgarashiS, et al.The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity2001;15:883. CrossRef

82. KuntzenT, TimmJ, BericalA, et al.Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment‐naive patients. Hepatology2008;48:1769. CrossRef

83. PhamTN, KingD, MacparlandSA, et al.Hepatitis C virus replicates in the same immune cell subsets in chronic hepatitis C and occult infection. Gastroenterology2008;134:812. CrossRef

84. CastilloI, Rodríguez‐IñigoE, BartoloméJ, et al.Hepatitis C virus replicates in peripheral blood mononuclear cells of patients with occult hepatitis C virus infection. Gut2005;54:682. CrossRef

85. WillemsM, PeerlinckK, MoshageH, et al.Hepatitis C virus‐RNAs in plasma and in peripheral blood mononuclear cells of hemophiliacs with chronic hepatitis C: evidence for viral replication in peripheral blood mononuclear cells. J Med Virol1994;42:272. CrossRef

86. MarukianS, JonesCT, AndrusL, et al.Cell culture‐produced hepatitis C virus does not infect peripheral blood mononuclear cells. Hepatology2008;48:1843. CrossRef

87. MellorJ, HaydonG, BlairC, et al.Low level or absent in vivo replication of hepatitis C virus and hepatitis G virus/GB virus C in peripheral blood mononuclear cells. J Gen Virol1998;79:705. CrossRef

88. FletcherNF, WilsonGK, MurrayJ, et al.Hepatitis C virus infects the endothelial cells of the blood‐brain barrier. Gastroenterology2012;142:634. CrossRef

89. SwainMG, LaiMY, ShiffmanML, et al.A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa‐2a and ribavirin. Gastroenterology2010;139:1593. CrossRef

90. MeylanE, CurranJ, HofmannK, et al.Cardif is an adaptor protein in the RIG‐I antiviral pathway and is targeted by hepatitis C virus. Nature2005;437:1167. CrossRef

91. BreimanA, GrandvauxN, LinR, et al.Inhibition of RIG‐I‐dependent signaling to the interferon pathway during hepatitis C virus expression and restoration of signaling by IKKepsilon. J Virol2005;79:3969. CrossRef

92. WangN, LiangY, DevarajS, et al.Toll‐like receptor 3 mediates establishment of an antiviral state against hepatitis C virus in hepatoma cells. J Virol2009;83:9824. CrossRef

93. EksiogluE, ZhuH, BayouthL, et al.Characterization of HCV interactions with Toll‐like receptors and RIG‐I in liver cells. PLoS ONE2011;6:e21186. CrossRef

94. SumpterRJr, LooYM, FoyE, et al.Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG‐I. J Virol2005;79:2689. CrossRef

95. MetzP, DazertE, RuggieriA, et al.Identification of type I and type II interferon‐induced effectors controlling hepatitis C virus replication. Hepatology2012;56:2082. CrossRef

96. ZhaoH, LinW, KumthipK, et al.A functional genomic screen reveals novel host genes that mediate interferon‐alpha's effects against hepatitis C virus. J Hepatol2012;56:326. CrossRef

97. SchogginsJW, WilsonSJ, PanisM, et al.A diverse range of gene products are effectors of the type I interferon antiviral response. Nature2011;472:481. CrossRef

98. LiXD, SunL, SethRB, et al.Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. Proc Natl Acad Sci U S A2005;102:17717. CrossRef

99. ChengG, ZhongJ, ChisariFV. Inhibition of dsRNA‐induced signaling in hepatitis C virus‐infected cells by NS3 protease‐dependent and ‐independent mechanisms. Proc Natl Acad Sci U S A2006;103:8499. CrossRef

100. LiK, FoyE, FerreonJC, et al.Immune evasion by hepatitis C virus NS3/4A protease‐mediated cleavage of the Toll‐like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci U S A2005;102:2992. CrossRef

101. Sarasin‐FilipowiczM, OakeleyEJ, DuongFH, et al.Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A2008;105:7034. CrossRef

102. FeldJJ, NandaS, HuangY, et al.Hepatic gene expression during treatment with peginterferon and ribavirin: identifying molecular pathways for treatment response. Hepatology2007;46:1548. CrossRef

103. AmadeiB, UrbaniS, CazalyA, et al.Activation of natural killer cells during acute infection with hepatitis C virus. Gastroenterology2010;138:1536. CrossRef

104. AhlenstielG, EdlichB, HogdalLJ, et al.Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C. Gastroenterology2011;141:1231. CrossRef

105. KhakooSI, ThioCL, MartinMP, et al.HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science2004;305:872. CrossRef

106. KamiliS, DrobeniucJ, AraujoAC, et al.Laboratory diagnostics for hepatitis C virus infection. Clin Infect Dis2012;55(Suppl 1):S43. CrossRef

107. YuMY, BartoschB, ZhangP, et al.Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti‐HCV‐positive plasma. Proc Natl Acad Sci U S A2004;101:7705. CrossRef

108. LogvinoffC, MajorME, OldachD, et al.Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc Natl Acad Sci U S A2004;101:10149. CrossRef

109. von HahnT, YoonJC, AlterH, et al.Hepatitis C virus continuously escapes from neutralizing antibody and T‐cell responses during chronic infection in vivo. Gastroenterology2007;132:667. CrossRef

110. HelleF, VieyresG, ElkriefL, et al.Role of N‐linked glycans in the functions of HCV envelope proteins incorporated into infectious virions. J Virol2010;84:11905. CrossRef

111. BrimacombeCL, GroveJ, MeredithLW, et al.Neutralizing antibody resistant hepatitis C virus cell‐to‐cell transmission. J Virol2011;85:596. CrossRef

112. MissaleG, BertoniR, LamonacaV, et al.Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti‐viral cell‐mediated immune response. J Clin Invest1996;98:706. CrossRef

113. LechnerF, WongDK, DunbarPR, et al.Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med2000;191:1499. CrossRef

114. LauerGM, BarnesE, LucasM, et al.High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. Gastroenterology2004;127:924. CrossRef

115. KaplanDE, SugimotoK, NewtonK, et al.Discordant role of CD4 T‐cell response relative to neutralizing antibody and CD8 T‐cell responses in acute hepatitis C. Gastroenterology2007;132:654. CrossRef

116. ShoukryNH, GrakouiA, HoughtonM, et al.Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J Exp Med2003;197:1645. CrossRef

117. NakamotoN, ChoH, ShakedA, et al.Synergistic reversal of intrahepatic HCV‐specific CD8 T cell exhaustion by combined PD‐1/CTLA‐4 blockade. PLoS Pathog2009;5:e1000313. CrossRef

118. Schulze zur WieschJ, CiuffredaD, Lewis‐XimenezL, et al.Broadly directed virus‐specific CD4+ T cell responses are primed during acute hepatitis C infection, but rapidly disappear from human blood with viral persistence. J Exp Med2012;209:61. CrossRef

119. McMahanRH, Golden‐MasonL, NishimuraMI, et al.Tim‐3 expression on PD‐1+ HCV‐specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte‐directed in vitro cytotoxicity. J Clin Invest2010;120:4546. CrossRef

120. WedemeyerH, HeXS, NascimbeniM, et al.Impaired effector function of hepatitis C virus‐specific CD8+ T cells in chronic hepatitis C virus infection. J Immunol2002;169:3447. CrossRef

121. SpangenbergHC, ViazovS, KerstingN, et al.Intrahepatic CD8+ T‐cell failure during chronic hepatitis C virus infection. Hepatology2005;42:828. CrossRef

122. Sekine‐OsajimaY, SakamotoN, MishimaK, et al.Development of plaque assays for hepatitis C virus‐JFH1 strain and isolation of mutants with enhanced cytopathogenicity and replication capacity. Virology2008;371:71. CrossRef

123. Rubbia‐BrandtL, QuadriR, AbidK, et al.Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol2000;33:106. CrossRef

124. Abdel‐HamidM, El‐DalyM, El‐KafrawyS, et al.Comparison of second‐ and third‐generation enzyme immunoassays for detecting antibodies to hepatitis C virus. J Clin Microbiol2002;40:1656. CrossRef

125. VrielinkH, ZaaijerHL, ReesinkHW, et al.Sensitivity and specificity of three third‐generation anti‐hepatitis C virus ELISAs. Vox Sang1995;69:14. CrossRef

126. BarreraJM, FrancisB, ErcillaG, et al.Improved detection of anti‐HCV in post‐transfusion hepatitis by a third‐generation ELISA. Vox Sang1995;68:15. CrossRef

127. CarithersRLJr, MarquardtA, GretchDR. Diagnostic testing for hepatitis C. Semin Liver Dis2000;20:159. CrossRef

128. CraxiA, ValenzaM, FabianoC, et al.Third‐generation hepatitis C virus tests in asymptomatic anti‐HCV‐positive blood donors. J Hepatol1994;21:730. CrossRef

129. MedhiS, PotukuchiSK, PolipalliSK, et al.Diagnostic utility of hepatitis C virus core antigen in hemodialysis patients. Clin Biochem2008;41:447. CrossRef

130. HadlichE, Alvares‐Da‐SilvaMR, Dal MolinRK, et al.Hepatitis C virus (HCV) viremia in HIV‐infected patients without HCV antibodies detectable by third‐generation enzyme immunoassay. J Gastroenterol Hepatol2007;22:1506. CrossRef

131. MacíasJ, BerenguerJ, JapónMA, et al.Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. Hepatology2009;50:1056. CrossRef

132. MederackeI, WedemeyerH, CiesekS, et al.Performance and clinical utility of a novel fully automated quantitative HCV‐core antigen assay. J Clin Virol2009;46:210. CrossRef

133. VermehrenJ, SusserS, BergerA, et al.Clinical utility of the ARCHITECT HCV Ag assay for early treatment monitoring in patients with chronic hepatitis C genotype 1 infection. J Clin Virol2012;55:17. CrossRef

134. YeoAE, GhanyM, Conry‐CantilenaC, et al.Stability of HCV‐RNA level and its lack of correlation with disease severity in asymptomatic chronic hepatitis C virus carriers. J Viral Hepat2001;8:256. CrossRef

135. ZechiniB, PasquazziC, AcetiA. Correlation of serum aminotransferases with HCV RNA levels and histological findings in patients with chronic hepatitis C: the role of serum aspartate transaminase in the evaluation of disease progression. Eur J Gastroenterol Hepatol2004;16:891. CrossRef

136. RossRS, ViazovSO, HoltzerCD, et al.Genotyping of hepatitis C virus isolates using CLIP sequencing. J Clin Microbiol2000;38:3581.

137. HalfonP, TrimouletP, BourliereM, et al.Hepatitis C virus genotyping based on 5′ noncoding sequence analysis (Trugene). J Clin Microbiol2001;39:1771. CrossRef

138. VerbeeckJ, StanleyMJ, ShiehJ, et al.Evaluation of Versant hepatitis C virus genotype assay (LiPA) 2.0. J Clin Microbiol2008;46:1901. CrossRef

139. BouchardeauF, CantaloubeJF, ChevaliezS, et al.Improvement of hepatitis C virus (HCV) genotype determination with the new version of the INNO‐LiPA HCV assay. J Clin Microbiol2007;45:1140. CrossRef

140. MartróE, GonzálezV, BucktonAJ, et al.Evaluation of a new assay in comparison with reverse hybridization and sequencing methods for hepatitis C virus genotyping targeting both 5′ noncoding and nonstructural 5b genomic regions. J Clin Microbiol2008;46:192. CrossRef

141. GermerJJ, MajewskiDW, YungB, et al.Evaluation of the invader assay for genotyping hepatitis C virus. J Clin Microbiol2006;44:318. CrossRef

142. ReinDB, SmithBD, WittenbornJS, et al.The cost‐effectiveness of birth‐cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med2012;156:263. CrossRef

143. McGarryLJ, PawarVS, PanchmatiaHR, et al.Economic model of a birth cohort screening program for hepatitis C virus. Hepatology2012;55:1344. CrossRef

144. ThomasDL, SeeffLB. Natural history of hepatitis C. Clin Liver Dis2005;9:383. CrossRef

145. OrlandJR, WrightTL, CooperS. Acute hepatitis C. Hepatology2001;33:321. CrossRef

146. CoxAL, NetskiDM, MosbrugerT, et al.Prospective evaluation of community‐acquired acute‐phase hepatitis C virus infection. Clin Infect Dis2005;40:951. CrossRef

147. GeD, FellayJ, ThompsonAJ, et al.Genetic variation in IL28B predicts hepatitis C treatment‐induced viral clearance. Nature2009;461:399. CrossRef

148. SuppiahV, MoldovanM, AhlenstielG, et al.IL28B is associated with response to chronic hepatitis C interferon‐alpha and ribavirin therapy. Nat Genet2009;41:1100. CrossRef

149. TanakaY, NishidaN, SugiyamaM, et al.Genome‐wide association of IL28B with response to pegylated interferon‐alpha and ribavirin therapy for chronic hepatitis C. Nat Genet2009;41:1105. CrossRef

150. ThomasDL, ThioCL, MartinMP, et al.Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature2009;461:798. CrossRef

151. TillmannHL, ThompsonAJ, PatelK, et al.A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology2010;139:1586. CrossRef

152. SarkarS, JiangZ, EvonDM, et al.Fatigue before, during and after antiviral therapy of chronic hepatitis C: results from the Virahep‐C study. J Hepatol2012;57:946. CrossRef

153. KallmanJ, O′NeilMM, LariveB, et al.Fatigue and health‐related quality of life (HRQL) in chronic hepatitis C virus infection. Dig Dis Sci2007;52:2531. CrossRef

154. PoynardT, CacoubP, RatziuV, et al.Fatigue in patients with chronic hepatitis C. J Viral Hepat2002;9:295. CrossRef

155. CacoubP, RatziuV, MyersRP, et al.Impact of treatment on extra hepatic manifestations in patients with chronic hepatitis C. J Hepatol2002;36:812. CrossRef

156. SeeffLB. Natural history of chronic hepatitis C. Hepatology2002;36(5 Suppl 1):S35. CrossRef

157. Kenny‐WalshE. Clinical outcomes after hepatitis C infection from contaminated anti‐D immune globulin. Irish Hepatology Research Group. N Engl J Med1999;340:1228. CrossRef

158. WieseM, BerrF, LafrenzM, et al.Low frequency of cirrhosis in a hepatitis C (genotype 1b) single‐source outbreak in germany: a 20‐year multicenter study. Hepatology2000;32:91. CrossRef

159. YanoM, KumadaH, KageM, et al.The long‐term pathological evolution of chronic hepatitis C. Hepatology1996;23:1334. CrossRef

160. TongMJ, el FarraNS, ReikesAR, et al.Clinical outcomes after transfusion‐associated hepatitis C. N Engl J Med1995;332:1463. CrossRef

161. NiederauC, LangeS, HeintgesT, et al.Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology1998;28:1687. CrossRef

162. FreemanAJ, DoreGJ, LawMG, et al.Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology2001;34:809. CrossRef

163. PoynardT, BedossaP, OpolonP. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet1997;349:825. CrossRef

164. PolS, FontaineH, CarnotF, et al.Predictive factors for development of cirrhosis in parenterally acquired chronic hepatitis C: a comparison between immunocompetent and immunocompromised patients. J Hepatol1998;29:12. CrossRef

165. HarrisDR, GoninR, AlterHJ, et al.The relationship of acute transfusion‐associated hepatitis to the development of cirrhosis in the presence of alcohol abuse. Ann Intern Med2001;134:120. CrossRef

166. FreemanAJ, LawMG, KaldorJM, et al.Predicting progression to cirrhosis in chronic hepatitis C virus infection. J Viral Hepat2003;10:285. CrossRef

167. SterlingRK, WegelinJA, SmithPG, et al.Similar progression of fibrosis between HIV/HCV‐infected and HCV‐infected patients: analysis of paired liver biopsy samples. Clin Gastroenterol Hepatol2010;8:1070. CrossRef

168. MontoA, KakarS, DoveLM, et al.Contributions to hepatic fibrosis in HIV‐HCV coinfected and HCV monoinfected patients. Am J Gastroenterol2006;101:1509. CrossRef

169. SulkowskiMS, MehtaSH, TorbensonMS, et al.Rapid fibrosis progression among HIV/hepatitis C virus‐co‐infected adults. AIDS2007;21:2209. CrossRef

170. BenhamouY, BochetM, Di MartinoV, et al.Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology1999;30:1054. CrossRef

171. DavisGL, AlterMJ, El‐SeragH, et al.Aging of hepatitis C virus (HCV)‐infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology2010;138:513. CrossRef

172. CliffordBD, DonahueD, SmithL, et al.High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology1995;21:613.

173. AbuafN, LunelF, GiralP, et al.Non‐organ specific autoantibodies associated with chronic C virus hepatitis. J Hepatol1993;18:359. CrossRef

174. LohseAW, GerkenG, MohrH, et al.Relation between autoimmune liver diseases and viral hepatitis: clinical and serological characteristics in 859 patients. Z Gastroenterol1995;33:527.

175. ArberN, KonikoffFM, MoshkowitzM, et al.Increased serum iron and iron saturation without liver iron accumulation distinguish chronic hepatitis C from other chronic liver diseases. Dig Dis Sci1994;39:2656. CrossRef

176. Di BisceglieAM, AxiotisCA, HoofnagleJH, et al.Measurements of iron status in patients with chronic hepatitis. Gastroenterology1992;102:2108.

177. ShanY, LambrechtRW, BonkovskyHL. Association of hepatitis C virus infection with serum iron status: analysis of data from the third National Health and Nutrition Examination Survey. Clin Infect Dis2005;40:834. CrossRef

178. SilviaIS, PerezRM, OliveiraPV, et al.Iron overload in patients with chronic hepatitis C virus infection: clinical and histological study. J Gastroenterol Hepatol2005;20:243. CrossRef

179. MarcellinP, BoyerN, GervaisA, et al.Long‐term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon‐alpha therapy. Ann Intern Med1997;127:875. CrossRef

180. MaylinS, Martinot‐PeignouxM, MoucariR, et al.Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology2008;135:821. CrossRef

181. Fernández‐RodríguezCM, AlonsoS, MartinezSM, et al.Peginterferon plus ribavirin and sustained virological response in HCV‐related cirrhosis: outcomes and factors predicting response. Am J Gastroenterol2010;105:2164. CrossRef

182. MorganTR, GhanyMG, KimHY, et al.Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology2010;52:833. CrossRef

183. van der MeerAJ, VeldtBJ, FeldJJ, et al.Association between sustained virological response and all‐cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA2012;308:2584. CrossRef

184. BrunoS, StroffoliniT, ColomboM, et al.Sustained virological response to interferon‐alpha is associated with improved outcome in HCV‐related cirrhosis: a retrospective study. Hepatology2007;45:579. CrossRef

185. MorganRL, BaackB, SmithBD, et al.Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta‐analysis of observational studies. Ann Intern Med2013;158:329. CrossRef

186. SingalAK, SinghA, JaganmohanS, et al.Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus‐related cirrhosis. Clin Gastroenterol Hepatol2010;8:192. CrossRef

187. VelosaJ, SerejoF, MarinhoR, et al.Eradication of hepatitis C virus reduces the risk of hepatocellular carcinoma in patients with compensated cirrhosis. Dig Dis Sci2011;56:1853. CrossRef

188. ShiratoriY, ItoY, YokosukaO, et al.Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med2005;142:105. CrossRef

189. HoofnagleJH, MullenKD, JonesDB, et al.Treatment of chronic non‐A,non‐B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med1986;315:1575. CrossRef

190. DavisGL, BalartLA, SchiffER, et al.Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med1989;321:1501. CrossRef

191. Di BisceglieAM, MartinP, KassianidesC, et al.Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double‐blind, placebo‐controlled trial. N Engl J Med1989;321:1506. CrossRef

192. PoynardT, LeroyV, CohardM, et al.Meta‐analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology1996;24:778. CrossRef

193. CarithersRLJr, EmersonSS. Therapy of hepatitis C: meta‐analysis of interferon alfa‐2b trials. Hepatology1997;26:83S. CrossRef

194. SidwellRW, HuffmanJH, KhareGP, et al.Broad‐spectrum antiviral activity of Virazole: 1‐beta‐D‐ribofuranosyl‐1,2,4‐triazole‐3‐carboxamide. Science1972;177:705. CrossRef

195. Di BisceglieAM, ConjeevaramHS, FriedMW, et al.Ribavirin as therapy for chronic hepatitis C. A randomized, double‐blind, placebo‐controlled trial. Ann Intern Med1995;123:897. CrossRef

196. DusheikoG, MainJ, ThomasH, et al.Ribavirin treatment for patients with chronic hepatitis C: results of a placebo‐controlled study. J Hepatol1996;25:591. CrossRef

197. McHutchisonJG, GordonSC, SchiffER, et al.Interferon alfa‐2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med1998;339:1485. CrossRef

198. PoynardT, MarcellinP, LeeSS, et al.Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet1998;352:1426. CrossRef

199. ReichardO, NorkransG, FrydenA, et al.Randomised, double‐blind, placebo‐controlled trial of interferon alpha‐2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet1998;351:83. CrossRef

200. ZhouS, LiuR, BaroudyBM, et al.The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA. Virology2003;310:333. CrossRef

201. RustgiVK, LeeWM, LawitzE, et al.Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders. Hepatology2009;50:1719. CrossRef

202. CrottyS, MaagD, ArnoldJJ, et al.The broad‐spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med2000;6:1375. CrossRef

203. BrochotE, DuverlieG, CastelainS, et al.Effect of ribavirin on the hepatitis C virus (JFH‐1) and its correlation with interferon sensitivity. Antivir Ther2007;12:805.

204. ContrerasAM, HiasaY, HeW, et al.Viral RNA mutations are region specific and increased by ribavirin in a full‐length hepatitis C virus replication system. J Virol2002;76:8505. CrossRef

205. HofmannWP, PoltaA, HerrmannE, et al.Mutagenic effect of ribavirin on hepatitis C nonstructural 5B quasispecies in vitro and during antiviral therapy. Gastroenterology2007;132:921. CrossRef

206. ChevaliezS, BrilletR, LázaroE, et al.Analysis of ribavirin mutagenicity in human hepatitis C virus infection. J Virol2007;81:7732. CrossRef

207. LutchmanG, DanehowerS, SongBC, et al.Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy. Gastroenterology2007;132:1757. CrossRef

208. ThomasE, FeldJJ, LiQ, et al.Ribavirin potentiates interferon action by augmenting interferon‐stimulated gene induction in hepatitis C virus cell culture models. Hepatology2011;53:32. CrossRef

209. TokumotoY, HiasaY, UesugiK, et al.Ribavirin regulates hepatitis C virus replication through enhancing interferon‐stimulated genes and interleukin 8. J Infect Dis2012;205:1121. CrossRef

210. MannsMP, McHutchisonJG, GordonSC, et al.Peginterferon alfa‐2b plus ribavirin compared with interferon alfa‐2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet2001;358:958. CrossRef

211. FriedMW, ShiffmanML, ReddyKR, et al.Peginterferon alfa‐2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med2002;347:975. CrossRef

212. ZeuzemS, Rodríguez‐TorresM, Rajender ReddyK, et al.Optimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterferon alfa‐2a/ribavirin. J Viral Hepat2012;19:766. CrossRef

213. PoordadF, BronowickiJP, GordonSC, et al.Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology2012;143:608. CrossRef

214. ZeuzemS, HultcrantzR, BourliereM, et al.Peginterferon alfa‐2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol2004;40:993. CrossRef

215. BresslerBL, GuindiM, TomlinsonG, et al.High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology2003;38:639. CrossRef

216. PattonHM, PatelK, BehlingC, et al.The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol2004;40:484. CrossRef

217. HeathcoteEJ, ShiffmanML, CooksleyWG, et al.Peginterferon alfa‐2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med2000;343:1673. CrossRef

218. ThompsonAJ, MuirAJ, SulkowskiMS, et al.Interleukin‐28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology2010;139:120. CrossRef

219. DavisGL, WongJB, McHutchisonJG, et al.Early virologic response to treatment with peginterferon alfa‐2b plus ribavirin in patients with chronic hepatitis C. Hepatology2003;38:645. CrossRef

220. MangiaA, SantoroR, MinervaN, et al.Peginterferon alfa‐2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med2005;352:2609. CrossRef

221. JensenDM, MorganTR, MarcellinP, et al.Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha‐2a (40 kd)/ribavirin therapy. Hepatology2006;43:954. CrossRef

222. FriedMW. Side effects of therapy of hepatitis C and their management. Hepatology2002;36(5 Suppl 1):S237. CrossRef

223. LohmannV, KornerF, KochJ, et al.Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science1999;285:110. CrossRef

224. BlightKJ, KolykhalovAA, RiceCM. Efficient initiation of HCV RNA replication in cell culture. Science2000;290:1972. CrossRef

225. LoveRA, PargeHE, WickershamJA, et al.The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin‐like fold and a structural zinc binding site. Cell1996;87:331. CrossRef

226. LamarreD, AndersonPC, BaileyM, et al.An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature2003;426:186. CrossRef

227. ReesinkHW, ZeuzemS, WeeginkCJ, et al.Rapid decline of viral RNA in hepatitis C patients treated with VX‐950: a phase Ib, placebo‐controlled, randomized study. Gastroenterology2006;131:997. CrossRef

228. SarrazinC, KiefferTL, BartelsD, et al.Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology2007;132:1767. CrossRef

229. BaconBR, GordonSC, LawitzE, et al.Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med2011;364:1207. CrossRef

230. PoordadF, McConeJJr, BaconBR, et al.Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med2011;364:1195. CrossRef

231. JacobsonIM, McHutchisonJG, DusheikoG, et al.Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med2011;364:2405. CrossRef

232. McHutchisonJG, MannsMP, MuirAJ, et al.Telaprevir for previously treated chronic HCV infection. N Engl J Med2010;362:1292. CrossRef

233. ShermanKE, FlammSL, AfdhalNH, et al.Response‐guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med2011;365:1014. CrossRef

234. ZeuzemS, AndreoneP, PolS, et al.Telaprevir for retreatment of HCV infection. N Engl J Med2011;364:2417. CrossRef

235. LawitzE, MangiaA, WylesD, et al.Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med2013;368:1878. CrossRef

236. AfdhalN, ZeuzemS, KwoP, et al.Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med2014;370:1889. CrossRef

237. AfdhalN, ReddyKR, NelsonDR, et al.Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med2014;370:1483. CrossRef

238. JacobsonIM, GordonSC, KowdleyKV, et al.Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med2013;368:1867. CrossRef

239. ZeuzemS, DusheikoGM, SalupereR, et al.Sofosbuvir + ribavirin for 12 or 24 weeks for patients with HCV genotype 2 or 3: the VALENCE trial. Hepatology2013;58(Suppl S1):730A.

240. De NicolaS, AghemoA, RumiMG, et al.Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4. Hepatology2012;55:336. CrossRef

241. KamalSM, El KamarySS, ShardellMD, et al.Pegylated interferon alpha‐2b plus ribavirin in patients with genotype 4 chronic hepatitis C: the role of rapid and early virologic response. Hepatology2007;46:1732. CrossRef

242. KamalSM, El TawilAA, NakanoT, et al.Peginterferon {alpha}‐2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. Gut2005;54:858. CrossRef

243. AntakiN, HermesA, HadadM, et al.Efficacy of interferon plus ribavirin in the treatment of hepatitis C virus genotype 5. J Viral Hepat2008;15:383. CrossRef

244. FungJ, LaiCL, HungI, et al.Chronic hepatitis C virus genotype 6 infection: response to pegylated interferon and ribavirin. J Infect Dis2008;198:808. CrossRef

245. LamKD, TrinhHN, DoST, et al.Randomized controlled trial of pegylated interferon‐alfa 2a and ribavirin in treatment‐naive chronic hepatitis C genotype 6. Hepatology2010;52:1573. CrossRef

246. Thu ThuyPT, BunchorntavakulC, Tan DatH, et al.A randomized trial of 48 versus 24 weeks of combination pegylated interferon and ribavirin therapy in genotype 6 chronic hepatitis C. J Hepatol2012;56:1012. CrossRef

247. RuanePJ, AinD, MeshrekeyR, et al.Sofosbuvir plus ribavirin, an interferon‐free regimen, in the treatment of treatment‐naïve and treatment–experienced patients with chronic genotype 4 HCV infection. J Hepatol2014;60:S503. CrossRef

248. RoomerR, HansenBE, JanssenHL, et al.Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C. Hepatology2010;52:1225. CrossRef

249. YangJF, HsiehMY, HouNJ, et al.Bacterial infection and neutropenia during peginterferon plus ribavirin combination therapy in patients with chronic hepatitis C with and without baseline neutropenia in clinical practice. Aliment Pharmacol Ther2009;29:1000. CrossRef

250. AntoniniMG, BabudieriS, MaidaI, et al.Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa‐2a or alfa‐2b plus ribavirin. Infection2008;36:250. CrossRef

251. SozaA, EverhartJE, GhanyMG, et al.Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology2002;36:1273. CrossRef

252. RoomerR, HansenBE, JanssenHL, et al.Thrombocytopenia and the risk of bleeding during treatment with peginterferon alfa and ribavirin for chronic hepatitis C. J Hepatol2010;53:455. CrossRef

253. McHutchisonJG, DusheikoG, ShiffmanML, et al.Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med2007;357:2227. CrossRef

254. LiuCH, KaoJH. Treatment of hepatitis C virus infection in patients with end‐stage renal disease. J Gastroenterol Hepatol2011;26:228. CrossRef

255. JacobsonIM, KowdleyKV, KwoPY. Anemia management in the era of triple combination therapy for chronic HCV. Gastroenterol Hepatol2012;8:1.

256. SulkowskiMS, ShiffmanML, AfdhalNH, et al.Hepatitis C virus treatment‐related anemia is associated with higher sustained virologic response rate. Gastroenterology2010;139:1602. CrossRef

257. MehtaN, MurthyUK, KaulV, et al.Outcome of retinopathy in chronic hepatitis C patients treated with peginterferon and ribavirin. Dig Dis Sci2010;55:452. CrossRef

258. VujosevicS, TempestaD, NoventaF, et al.Pegylated interferon‐associated retinopathy is frequent in hepatitis C virus patients with hypertension and justifies ophthalmologic screening. Hepatology2012;56:455. CrossRef

259. BurgerD, BackD, BuggischP, et al.Clinical management of drug‐drug interactions in HCV therapy: challenges and solutions. J Hepatol2013;58:792. CrossRef

260. CoreyKE, Mendez‐NavarroJ, GorospeEC, et al.Early treatment improves outcomes in acute hepatitis C virus infection: a meta‐analysis. J Viral Hepat2010;17:201. CrossRef

261. GerlachJT, DiepolderHM, ZachovalR, et al.Acute hepatitis C: high rate of both spontaneous and treatment‐induced viral clearance. Gastroenterology2003;125:80. CrossRef

262. JaeckelE, CornbergM, WedemeyerH, et al.Treatment of acute hepatitis C with interferon alfa‐2b. N Engl J Med2001;345:1452. CrossRef

263. CoreyKE, RossAS, WurcelA, et al.Outcomes and treatment of acute hepatitis C virus infection in a United States population. Clin Gastroenterol Hepatol2006;4:1278. CrossRef

264. LamperticoP, RumiM, RomeoR, et al.A multicenter randomized controlled trial of recombinant interferon‐alpha 2b in patients with acute transfusion‐associated hepatitis C. Hepatology1994;19:19. CrossRef

265. CalleriG, ColombattoP, GozzelinoM, et al.Natural beta interferon in acute type‐C hepatitis patients: a randomized controlled trial. Ital J Gastroenterol Hepatol1998;30:181.

266. NomuraH, SouS, TanimotoH, et al.Short‐term interferon‐alfa therapy for acute hepatitis C: a randomized controlled trial. Hepatology2004;39:1213. CrossRef

267. HwangSJ, LeeSD, ChanCY, et al.A randomized controlled trial of recombinant interferon alpha‐2b in the treatment of Chinese patients with acute post‐transfusion hepatitis C. J Hepatol1994;21:831. CrossRef

268. TakanoS, SatomuraY, OmataM. Effects of interferon beta on non‐A, non‐B acute hepatitis: a prospective, randomized, controlled‐dose study. Japan Acute Hepatitis Cooperative Study Group. Gastroenterology1994;107:805. CrossRef

269. De RosaFG, BargiacchiO, AudagnottoS, et al.Twelve‐week treatment of acute hepatitis C virus with pegylated interferon‐ alpha ‐2b in injection drug users. Clin Infect Dis2007;45:583. CrossRef

270. KamalSM, MoustafaKN, ChenJ, et al.Duration of peginterferon therapy in acute hepatitis C: a randomized trial. Hepatology2006;43:923. CrossRef

271. KamalSM, FoulyAE, KamelRR, et al.Peginterferon alfa‐2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology2006;130:632. CrossRef

272. WiegandJ, BuggischP, BoecherW, et al.Early monotherapy with pegylated interferon alpha‐2b for acute hepatitis C infection: the HEP‐NET acute‐HCV‐II study. Hepatology2006;43:250. CrossRef

273. SantantonioT, FasanoM, SinisiE, et al.Efficacy of a 24‐week course of PEG‐interferon alpha‐2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance. J Hepatol2005;42:329. CrossRef

274. WeberR, SabinCA, Friis‐MollerN, et al.Liver‐related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med2006;166:1632. CrossRef

275. LinW, WeinbergEM, ChungRT. Pathogenesis of accelerated fibrosis in HIV/HCV co‐infection. J Infect Dis2013;207(Suppl 1):S13. CrossRef

276. SulkowskiMS, MehtaSH, TorbensonMS, et al.Rapid fibrosis progression among HIV/hepatitis C virus‐co‐infected adults. AIDS2007;21:2209. CrossRef

277. TorrianiFJ, Rodriguez‐TorresM, RockstrohJK, et al.Peginterferon Alfa‐2a plus ribavirin for chronic hepatitis C virus infection in HIV‐infected patients. N Engl J Med2004;351:438. CrossRef

278. ChungRT, AndersenJ, VolberdingP, et al.Peginterferon Alfa‐2a plus ribavirin versus interferon alfa‐2a plus ribavirin for chronic hepatitis C in HIV‐coinfected persons. N Engl J Med2004;351:451. CrossRef

279. CarratF, Bani‐SadrF, PolS, et al.Pegylated interferon alfa‐2b vs standard interferon alfa‐2b, plus ribavirin, for chronic hepatitis C in HIV‐infected patients: a randomized controlled trial. JAMA2004;292:2839. CrossRef

280. LinW, WuG, LiS, et al.HIV and HCV cooperatively promote hepatic fibrogenesis via induction of reactive oxygen species and NFkappaB. J Biol Chem2011;286:2665. CrossRef

281. JangJY, ShaoRX, LinW, et al.HIV infection increases HCV‐induced hepatocyte apoptosis. J Hepatol2011;54:612. CrossRef

282. BalagopalA, PhilpFH, AstemborskiJ, et al.Human immunodeficiency virus‐related microbial translocation and progression of hepatitis C. Gastroenterology2008;135:226. CrossRef

283. SulkowskiM, NaggieS, LalezariJ, et al.Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA2014;312:353. CrossRef

284. ConjeevaramHS, FriedMW, JeffersLJ, et al.Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology2006;131:470. CrossRef

285. MuirAJ, BornsteinJD, KillenbergPG. Peginterferon alfa‐2b and ribavirin for the treatment of chronic hepatitis C in blacks and non‐Hispanic whites. N Engl J Med2004;350:2265. CrossRef

286. JeffersLJ, CassidyW, HowellCD, et al.Peginterferon alfa‐2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology2004;39:1702. CrossRef

287. Peck‐RadosavljevicM, BoletisJ, BesisikF, et al.Low‐dose peginterferon alfa‐2a is safe and produces a sustained virologic response in patients with chronic hepatitis C and end‐stage renal disease. Clin Gastroenterol Hepatol2011;9:242. CrossRef

288. GuptaSK, KantesariaB, GlueP. Pharmacokinetics, safety, and tolerability of ribavirin in hemodialysis‐dependent patients. Eur J Clin Pharmacol2012;68:415. CrossRef

289. BaidS, Tolkoff‐RubinN, SaidmanS, et al.Acute humoral rejection in hepatitis C‐infected renal transplant recipients receiving antiviral therapy. Am J Transplant2003;3:74. CrossRef

290. MagnoneM, HolleyJL, ShapiroR, et al.Interferon‐alpha‐induced acute renal allograft rejection. Transplantation1995;59:1068. CrossRef

291. BzowejN, NelsonDR, TerraultNA, et al.PHOENIX: a randomized controlled trial of peginterferon alfa‐2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transpl2011;17:528. CrossRef

292. SelznerN, RennerEL, SelznerM, et al.Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long‐term outcome. Transplantation2009;88:1214. CrossRef

293. SchmidtSC, BahraM, BayraktarS, et al.Antiviral treatment of patients with recurrent hepatitis C after liver transplantation with pegylated interferon. Dig Dis Sci2010;55:2063. CrossRef

294. BalbiE, LealCR, Pacheco‐MoreiraLF, et al.Treatment for recurrent hepatitis C virus infection after liver transplantation. Transplant Proc2009;41:891. CrossRef

295. DingesS, MorardI, HeimM, et al.Pegylated interferon‐alpha2a/ribavirin treatment of recurrent hepatitis C after liver transplantation. Transpl Infect Dis2009;11:33. CrossRef

296. LodatoF, BerardiS, GramenziA, et al.Clinical trial: peg‐interferon alfa‐2b and ribavirin for the treatment of genotype‐1 hepatitis C recurrence after liver transplantation. Aliment Pharmacol Ther2008;28:450. CrossRef

297. CurryMP, FornsX, ChungR, et al.Pretransplant sofosbuvir and ribavirin to prevent recurrence of HCV infection after liver transplantation. Hepatology2013;58(Suppl S1):313A.

298. SamuelD, CharltonM, GaneE, et al.Sofosbuvir and ribavirin for the treatment of recurrent hepatitis C infection after liver transplantation: results of a prospective, multicenter study. J Hepatol2014;60:S499. CrossRef

299. SummaV, LudmererSW, McCauleyJA, et al.MK‐5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother2012;56:4161. CrossRef

300. SulkowskiMS, AsselahT, LalezariJ, et al.Faldaprevir combined with peginterferon alfa‐2a and ribavirin in treatment‐naïve patients with chronic genotype‐1 HCV: SILEN‐C1 trial. Hepatology2013;57:2143. CrossRef

301. O′MearaJA, LemkeCT, GodboutC, et al.Molecular mechanism by which a potent hepatitis C virus NS3‐NS4A protease inhibitor overcomes emergence of resistance. J Biol Chem2013;288:5673. CrossRef

302. NettlesR, ChienC, ChungE, et al.BMS‐790052 is a first‐in‐class potent hepatitis C virus (HCV) NS5A inhibitor for patients with chronic HCV infection: results from a proof‐of‐concept study. Hepatology2008;48(4 Suppl):1025A. CrossRef

303. FridellRA, WangC, SunJH, et al.Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS‐790052 in humans: in vitro and in vivo correlations. Hepatology2011;54:1924. CrossRef

304. GerberL, WelzelTM, ZeuzemS. New therapeutic strategies in HCV: polymerase inhibitors. Liver Int2013;33:85. CrossRef

305. LudmererSW, GrahamDJ, BootsE, et al.Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay. Antimicrob Agents Chemother2005;49:2059. CrossRef

306. HopkinsS, DimassimoB, RusnakP, et al.The cyclophilin inhibitor SCY‐635 suppresses viral replication and induces endogenous interferons in patients with chronic HCV genotype 1 infection. J Hepatol2012;57:47. CrossRef

307. FlisiakR, FeinmanSV, JablkowskiM, et al.The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment‐naïve hepatitis C patients. Hepatology2009;49:1460. CrossRef

308. JoplingCL, YiM, LancasterAM, et al.Modulation of hepatitis C virus RNA abundance by a liver‐specific MicroRNA. Science2005;309:1577. CrossRef

309. LanfordRE, Hildebrandt‐EriksenES, PetriA, et al.Therapeutic silencing of microRNA‐122 in primates with chronic hepatitis C virus infection. Science2010;327:198. CrossRef

310. LokAS, GardinerDF, LawitzE, et al.Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med2012;366:216. CrossRef

311. LawitzE, SulkowskiMS, GhalibR, et al.Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non‐responders to pegylated interferon and ribavirin nand treatment‐naïve patients: the COSMOS randomised study. Lancet2014;epub ahead of print.

312. FeldJJ, KowdleyKV, CoakleyE, et al.Treatment of HCV with ABT‐450/r‐ombitasvir and dasabuvir with ribavirin. N Engl J Med2014;370:1594. CrossRef

313. PoordadF, HezodeC, TrinhR, et al.ABT‐450/r‐ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med2014;370:1973. CrossRef

314. ZeuzemS, JacobsonIM, BaykalT, et al.Retreatment of HCV with ABT‐450/r‐ombitasvir and dasabuvir with ribavirin. N Engl J Med2014;370:1604. CrossRef

315. AlazawiW, CunninghamM, DeardenJ, et al.Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection. Aliment Pharmacol Ther2010;32:344. CrossRef

316. LokAS, SeeffLB, MorganTR, et al.Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C‐related advanced liver disease. Gastroenterology2009;136:138. CrossRef

317. CardosoAC, MoucariR, Figueiredo‐MendesC, et al.Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol2010;52:652. CrossRef

318. CzajaAJ, CarpenterHA, SantrachPJ, et al.Significance of human leukocyte antigens DR3 and DR4 in chronic viral hepatitis. Dig Dis Sci1995;40:2098. CrossRef

319. LunelF, AbuafN, FrangeulL, et al.Liver/kidney microsome antibody type 1 and hepatitis C virus infection. Hepatology1992;16:630. CrossRef

320. Codoner‐FranchP, OrdinanaV, GascoE, et al.Anti‐rat liver microsomal and cytosolic antibodies in hepatitis C virus infection. Autoimmunity1994;17:89. CrossRef

321. MuratoriL, LenziM, MaY, et al.Heterogeneity of liver/kidney microsomal antibody type 1 in autoimmune hepatitis and hepatitis C virus related liver disease. Gut1995;37:406. CrossRef

322. StrassburgCP, Obermayer‐StraubP, MannsMP. Autoimmunity in hepatitis C and D virus infection. J Viral Hepat1996;3:49. CrossRef

323. NishiguchiS, KurokiT, UedaT, et al.Detection of hepatitis C virus antibody in the absence of viral RNA in patients with autoimmune hepatitis. Ann Intern Med1992;116:21. CrossRef

324. McFarlaneIG, SmithHM, JohnsonPJ, et al.Hepatitis C virus antibodies in chronic active hepatitis: pathogenetic factor or false‐positive result?Lancet1990;335:754. CrossRef

325. Loustaud‐RattiV, LunelF. [Extrahepatic manifestations of hepatitis C virus infection]. Rev Prat2000;50:1089.

326. AgnelloV, ChungRT, KaplanLM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med1992;327:1490. CrossRef

327. PhilipneriM, BastaniB. Kidney disease in patients with chronic hepatitis C. Curr Gastroenterol Rep2001;3:79. CrossRef

328. MehtaSH, BrancatiFL, SulkowskiMS, et al.Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med2000;133:592. CrossRef

329. KnoblerH, SchihmanterR, ZifroniA, et al.Increased risk of type 2 diabetes in noncirrhotic patients with chronic hepatitis C virus infection. Mayo Clin Proc2000;75:355. CrossRef

330. Delgado‐BorregoA, KamegayaY, JordanSH, et al.HCV synergizes with body weight in the promotion of insulin resistance. J Viral Hepat2011;18:135. CrossRef

331. Delgado‐BorregoA, JordanSH, NegreB, et al.Reduction of insulin resistance with effective clearance of hepatitis C infection: results from the HALT‐C trial. Clin Gastroenterol Hepatol2010;8:458. CrossRef

332. HoofnagleJH, SeeffLB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med2006;355:2444. CrossRef

333. TranA, QuarantaJF, BenzakenS, et al.High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before interferon therapy. Hepatology1993;18:253. CrossRef

334. BerkDR, MallorySB, KeeffeEB, et al.Dermatologic disorders associated with chronic hepatitis C: effect of interferon therapy. Clin Gastroenterol Hepatol2007;5:142. CrossRef

335. van der MeijEH, van der WaalI. Hepatitis C virus infection and oral lichen planus: a report from The Netherlands. J Oral Pathol Med2000;29:255. CrossRef

336. PyrsopoulosNT, ReddyKR. Extrahepatic manifestations of chronic viral hepatitis. Curr Gastroenterol Rep2001;3:71. CrossRef

337. CacoubP, MaisonobeT, ThibaultV, et al.Systemic vasculitis in patients with hepatitis C. J Rheumatol2001;28:109.

338. FineKD, OgunjiF, SaloumY, et al.Celiac sprue: another autoimmune syndrome associated with hepatitis C. Am J Gastroenterol2001;96:138. CrossRef

339. AlricL, PartenskyJ, ReynaudD, et al.Association between polymyositis and hepatitis C infection. Treatment‐related difficulties. Rev Med Interne2000;21:542. CrossRef

340. Abu‐ShakraM, SukenikS, BuskilaD. Systemic sclerosis: another rheumatic disease associated with hepatitis C virus infection. Clin Rheumatol2000;19:378. CrossRef

341. Ramos‐CasalsM, FontJ, Garcia‐CarrascoM, et al.Hepatitis C virus infection mimicking systemic lupus erythematosus: study of hepatitis C virus infection in a series of 134 Spanish patients with systemic lupus erythematosus. Arthritis Rheum2000;43:2801. CrossRef

342. ArcainiL, MerliM, VolpettiS, et al.Indolent B‐cell lymphomas associated with HCV infection: clinical and virological features and role of antiviral therapy. Clin Dev Immunol2012;2012:638185. CrossRef

343. ZignegoAL, GianniniC, GragnaniL. HCV and lymphoproliferation. Clin Dev Immunol2012;2012:980942. CrossRef

344. Hartridge‐LambertSK, SteinEM, MarkowitzAJ, et al.Hepatitis C and non‐Hodgkin lymphoma: the clinical perspective. Hepatology2012;55:634. CrossRef

345. LawM, MaruyamaT, LewisJ, et al.Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med2008;14:25. CrossRef

346. KeckZY, XiaJ, WangY, et al.Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate. PLoS Pathog2012;8:e1002653. CrossRef

347. SchianoTD, CharltonM, YounossiZ, et al.Monoclonal antibody HCV‐AbXTL68 in patients undergoing liver transplantation for HCV: results of a phase 2 randomized study. Liver Transpl2006;12:1381. CrossRef

348. DavisGL, NelsonDR, TerraultN, et al.A randomized, open‐label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients. Liver Transpl2005;11:941. CrossRef

349. BarnesE, FolgoriA, CaponeS, et al.Novel adenovirus‐based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med2012;4:115ra1. CrossRef

350. HabersetzerF, HonnetG, BainC, et al.A poxvirus vaccine is safe, induces T‐cell responses, and decreases viral load in patients with chronic hepatitis C. Gastroenterology2011;141:890. CrossRef

351. KladeCS, WedemeyerH, BergT, et al.Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. Gastroenterology2008;134:1385. CrossRef